Hep Magazine

Hep is a highly regarded print and online resource dedicated to individuals affected by viral hepatitis. Since its inception in 2010, Hep and its website, HepMag.com, have provided top-quality editorial content, making them a trusted source for education and support for those living with hepatitis. At Smart + Strong, Hep's parent organization, we believe that having access to reliable health information, feeling empowered to advocate for your own needs, and connecting with others facing similar health challenges can significantly improve your chances of thriving. Smart + Strong produces health-oriented magazines and websites that unite a wide range of individuals to disseminate crucial information. These platforms allow you to share your experiences with healthcare providers, insurance companies, the media, government entities, and each other, highlighting what it means to live with and overcome various health issues.

Consumer

English

Magazine, Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#2522447

United States

#718245

Health/Health Conditions and Concerns

#2065

Traffic sources

Monthly visitors

Articles

Fatty Liver Disease Is Expected to Skyrocket By 20250

1 month ago | hepmag.com | Sukanya Charuchandra

Without better detection and effective treatment, the clinical burden of metabolic dysfunction-associated fatty liver disease (MASLD) is expected to rise dramatically over the next 30 years, with cases of decompensated cirrhosis more than tripling, liver cancer nearly doubling and liver transplants increasing almost fourfold. Researchers generated these projections, which were published in JAMA Network Open, using a simulation model.
HIV/HBV/HDV Triple Infection Linked to Liver-Related Death

2 months ago | hepmag.com | Sukanya Charuchandra

Among people with HIV and hepatitis B virus (HBV) coinfection, “superinfection” with hepatitis D virus (HDV) is a serious risk factor for liver-related death despite antiviral treatment, according to study findings published in Clinical Infectious Diseases. HIV and hepatitis B have overlapping transmission routes, and around 10% of people living with HIV worldwide also have HBV.
Efruxifermin Improves Liver Cirrhosis in People With MASH

2 months ago | hepmag.com | Liz Highleyman

Efruxifermin, a fibroblast growth factor analog, led to regression of liver fibrosis in people with metabolic dysfunction-associated steatohepatitis (MASH) and compensated cirrhosis, Akero Therapeutics announced this week. If approved, it could become the first medication for people with the most advanced stage of fibrosis due to fatty liver disease.
Scientists Identify Three Types of Fatty Liver Disease

Jan 6, 2025 | hepmag.com | Sukanya Charuchandra

Looking at two separate Chinese cohorts, researchers identified three different molecular subtypes linked to the risk of advancing non-alcoholic fatty liver disease (NAFLD), according to study results published in Science Translational Medicine.
Denifanstat Shows Promise for Advanced Fatty Liver Disease

Oct 24, 2024 | hepmag.com | Liz Highleyman

Denifanstat, an oral fatty acid synthase inhibitor, led to significant improvements in people with metabolic dysfunction-associated steatohepatitis (MASH), according to study results published in The Lancet Gastroenterology & Hepatology. The Phase IIb FASCINATE-2 trial found that people treated with denifanstat were more than twice as likely as placebo recipients to experience an improvement in disease activity, MASH resolution and a reduction in liver fibrosis.
Low-Income Adolescents Are at Higher Risk for Fatty Liver Disease

Oct 14, 2024 | hepmag.com | Sukanya Charuchandra

Adolescents who grow up in low-income households or with a parent with a low education level and those who lack adequate health food have a significantly higher risk for metabolic dysfunction-associated steatotic liver disease (MASLD), according to findings published in The American Journal of Gastroenterology. Latino teens may be especially at risk for fatty liver disease.
National African Immigrant and Refugee HIV/AIDS and Hepatitis Awareness Day 2024

Sep 9, 2024 | hepmag.com | Trenton Straube

Monday, September 9, is National African Immigrant and Refugee HIV/AIDS and Hepatitis Awareness Day (#NAIRHHADay) 2024. This year marks the 10th anniversary of the event. It is a chance to address HIV, AIDS and hepatitis B inequities among African immigrant communities in the United States and to advocate for resources and funding to foster healthier communities. An African proverb says “Not to know is bad. Not to wish to know is worse.” Knowledge is power! Be your own best...
Tattoos and Hepatitis C: What Are the Risks?

Sep 2, 2024 | hepmag.com | Liz Highleyman

Tatoos done under sterile conditions are safe, but unsterile tattooing can transmit the bloodborne hepatitis C virus (HCV), as well as hepatitis B and HIV. What do you need to know to avoid acquiring HCV while getting a tattoo? Here are some answers to common questions. How can hepatitis C be transmitted through tattooing?
10 States Allow Health Insurers to Ignore Co-Pay Assistance Rules

Aug 30, 2024 | hepmag.com | Trenton Straube

A report by The AIDS Institute found that 21 health insurance providers in 10 states violate rules regarding co-pay accumulator adjustment policies (CAAPs). Specifically, the insurers are not counting co-pay assistance toward enrollees’ deductibles, despite state laws and a federal ruling prohibiting the practice. Failure to enforce laws regarding co-pay adjustments can increase the out-of-pocket costs participants must pay for their prescription meds.
Seladelpar Gets Accelerated Approval for Autoimmune Liver Disease

Aug 15, 2024 | hepmag.com | Liz Highleyman

The Food and Drug Administration (FDA) this week granted accelerated approval of seladelpar (brand name Livdelzi) for primary biliary cholangitis (PBC), a rare autoimmune disease affecting the bile ducts and liver. Another medication in the same class, elafibranor (brand name Iqirvo), received accelerated approval in June.